Rhythm Pharmaceuticals Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Rhythm Pharmaceuticals stock.
View analyst ratings for Rhythm Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Rhythm Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Rhythm Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Rhythm Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) posted its quarterly earnings results on Sunday, May, 2nd. The company reported ($1.16) EPS for the quarter, missing the consensus estimate of $0.30 by $1.46.
View Rhythm Pharmaceuticals' earnings history.

Rhythm Pharmaceuticals' stock was trading at $15.00 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RYTM shares have increased by 27.2% and is now trading at $19.08.
View which stocks have been most impacted by COVID-19.

6 equities research analysts have issued twelve-month target prices for Rhythm Pharmaceuticals' shares. Their forecasts range from $33.00 to $67.00. On average, they anticipate Rhythm Pharmaceuticals' stock price to reach $50.67 in the next twelve months. This suggests a possible upside of 165.5% from the stock's current price.
View analysts' price targets for Rhythm Pharmaceuticals or view top-rated stocks among Wall Street analysts.

1 employees have rated Rhythm Pharmaceuticals CEO on Glassdoor.com. has an approval rating of 100% among Rhythm Pharmaceuticals' employees. This puts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Rhythm Pharmaceuticals include Karuna Therapeutics (KRTX), Agios Pharmaceuticals (AGIO), Turning Point Therapeutics (TPTX), Intra-Cellular Therapies (ITCI), Emergent BioSolutions (EBS), Nektar Therapeutics (NKTR), PTC Therapeutics (PTCT), Insmed (INSM), IGM Biosciences (IGMS), Rocket Pharmaceuticals (RCKT), Nuvation Bio (NUVB), Taro Pharmaceutical Industries (TARO), Amicus Therapeutics (FOLD), MorphoSys (MOR) and Cryoport (CYRX).
View all of RYTM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

(RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

Rhythm Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Primecap Management Co. CA (11.96%), RA Capital Management L.P. (9.70%), Janus Henderson Group PLC (8.14%), Baker BROS. Advisors LP (6.93%), BlackRock Inc. (6.26%) and Federated Hermes Inc. (6.20%). Company insiders that own Rhythm Pharmaceuticals stock include David P Meeker, Nithya Desikan, Ra Capital Management, LP and Todd Foley.
View institutional ownership trends for Rhythm Pharmaceuticals.

RYTM stock was sold by a variety of institutional investors in the last quarter, including MPM Asset Management LLC, Deerfield Management Company L.P. Series C, Janus Henderson Group PLC, Dimensional Fund Advisors LP, SG Americas Securities LLC, Credit Suisse AG, UBS Asset Management Americas Inc., and JPMorgan Chase & Co.. Company insiders that have sold Rhythm Pharmaceuticals company stock in the last year include Nithya Desikan, Ra Capital Management, LP, and Todd Foley.
View insider buying and selling activity for Rhythm Pharmaceuticals or view top insider-selling stocks.

RYTM stock was bought by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Baker BROS. Advisors LP, Gilder Gagnon Howe & Co. LLC, RA Capital Management L.P., Caas Capital Management LP, Goldman Sachs Group Inc., Federated Hermes Inc., and BlackRock Inc..
View insider buying and selling activity for Rhythm Pharmaceuticals or or view top insider-buying stocks.

Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RYTM stock can currently be purchased for approximately $19.08.

Rhythm Pharmaceuticals has a market capitalization of $958.01 million. The company earns $-134,000,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis.

Rhythm Pharmaceuticals employs 90 workers across the globe.

The official website for Rhythm Pharmaceuticals is www.rhythmtx.com.

Rhythm Pharmaceuticals is headquartered at 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116.

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]